24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling

Abstract Background The SAKK 19/05 trial investigated the safety and efficacy of the combined targeted therapy bevacizumab and erlotinib (BE) in unselected patients with advanced non-squamous non-small cell lung cancer (NSCLC). Although activating EGFR mutations were the strongest predictors of the...

Full description

Bibliographic Details
Main Authors: Florent Baty, Markus Joerger, Martin Früh, Dirk Klingbiel, Francesco Zappa, Martin Brutsche
Format: Article
Language:English
Published: BMC 2017-03-01
Series:Journal of Translational Medicine
Subjects:
Non-small cell lung cancer
Combined targeted therapies
Blood predictive markers
Exon arrays
Online Access:http://link.springer.com/article/10.1186/s12967-017-1174-z

Internet

http://link.springer.com/article/10.1186/s12967-017-1174-z

Similar Items